NCKAP5L

Across TCGA pan-cancer cohorts, NCKAP5L Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated NCKAP5L data layer compared with 24 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher NCKAP5L Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated NCKAP5L expression acts as an unfavorable survival marker.

LIHC, KIRP, and BRCA are the cancer types where NCKAP5L Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Median	All	0.303	0.783	<.001	39	view →
KIRP	OS	Median	All	0.272	0.885	<.001	12	view →
BRCA	OS	Median	All	0.120	0.578	.021	12	view →
UCEC	OS	Median	IV	0.259	0.770	<.001	12	view →
LUAD	DFS	Median	II,III,IV	0.349	0.686	.006	10	view →
PAAD	OS	Median	All	0.131	0.640	.012	6	view →
HNSC	DFS	Median	II,III,IV	0.172	0.593	.038	3	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

NCKAP5L–LIHC (OS)

Open the LIHC breakdown →